The contribution of community pharmacists during the COVID-19 pandemic
Disease Management Services
21
Disease Management Services
Directly observed treatment/Supervised Consumption of Medicines
First time dispensing intervention (e.g. New Medicines Service)
Administering injectable medicines (e.g. antibiotics)
Instruction on use of therapeutic, self-monitoring device or medical aid (e.g. stoma appliance, inhaler, insulin device)
Teleconsultations by pharmacists
Therapeutic Adherence Support
Chronic disease management (e.g. hypertension, hyperlipidemia, diabetes, asthma, COPD, NOAC)
Data Collection on the effectivness of new medicines
4
1
3
2
3
2
1
5
2
9
3
6
7
7
5
3
1
2
3
1
Remunerated by Government/Health Payer
Provided in most pharmacies under contract, agreement or regulation
Provided in some pharmacies as pilot
Number of European countries
PGEU Annual Report 2021
Community pharmacists exemplar role as primary care providers in the COVID-19 pandemic
X
PGEU Members 2021
PGEU Executive Committee 2021
PGEU Secretariat
A look forward
2021 at a glance
Foreword Alain Delgutte,
PGEU President 2021
The contribution of community
pharmacists during the COVID-19